Dicerna announced the presentation of updated data from its ongoing PHYOX1 Phase 1 clinical trial evaluating DCR-PHXC, the company’s lead GalXC product candidate. The data showed post-dose reductions in 24-hour urinary oxalate levels in adult and adolescent study participants with primary hyperoxaluria type 1 and type 2. Investigators reported that a single dose of DCR-PHXC led to normalization or near-normalization of urinary oxalate levels in a majority of participants and was generally well-tolerated. The data were presented in a poster on March 28 at the German Society of Pediatric Nephrology 50th Annual Meeting in Cologne, Germany.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.